Gossamer Bio, Inc.
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for seralutinib in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“PROSERA CT FRI Sub-Study Topline Results • The PROSERA CT functional respiratory imaging (FRI) exploratory substudy (n = 162) demonstrated multiple statistically significant exploratory treatment effects across arterial, venous, fibrosis re”